@StockTwits thanks guys. I very much appreciate the opportunity to hang out here today. $EXCHTALK. I <3 StockTwits

Thanks for joining me here. The half hour flies by fast. Need to get back to my ASCO prep. Please follow my coverage this weekend. $EXCHTALK

If you want to follow my coverage of ASCO, i will be live-blogging Sat-Mon. You'll find me at www.thestreet.com & twitter $EXCHTALK

@Techinsidr My uber-bearish position on $CVM is well known. It's a beast all right, but for all the wrong reasons. $EXCHTALK

Once ASCO ends, bios tend to go into the summer slumber and u do see significant selling. That's often a buying oppty. $EXCHTALK

@adamfeuerstein Hey Adam - any thoughts on $CVM? Got some friends who are convinced it's a beast... $EXCHTALK

@TomSchiavone could precipitate post-asco sell off, for sure. Is there any fundamental reason $ONTY doubling since March? $EXCHTALK

@adamfeuerstein Any larger names that might move in sympathy with any news breaking from ASCO? Like a $PFE or $MRK? $EXCHTALK

@dominicrivera I'm lousy with takeover predictions. Fortunately, i'm not alone. $EXCHTALK

@TomSchiavone I should mention $ONTY is a cancer immunotherapy story, so everyone wants to think they've found the next $DNDN. $EXCHTALK

@BioRunUp $OREX is not ASCO stock but hard to see how FDA gives them a break on the follow up study needed for its obesity drug. $EXCHTALK

@TomSchiavone $ONTY is interesting too, in that it won't have a meaningful presence at ASCO. $EXCHTALK